The cystic fibrosis (CF) specialist Proteostasis Therapeutics (Nasdaq: PTI) made gains of 47% in Tuesday morning’s trading as it entered the afternoon at $6.13 per share.
Investors were reacting to news that the company has received Breakthrough Therapy designation from the US Food and Drug Administration (FDA) for PTI-428, its CF transmembrane conductance regulator (CFTR) amplifier.
The status applies for the treatment of CF in homozygous patients for the F508del mutation who are receiving Vertex Pharmaceuticals’ (Nasdaq: VRTX) Orkambi (lumacaftor/ivacaftor) as background therapy.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze